Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib and Pegylated IFN-alpha 2b in Metastatic Renal Cell Carcinoma
NCT02447887Phase 2Terminated
- Sponsor
- Fox Chase Cancer Center
- Start
- Aug 2015
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ixazomib in renal cell carcinoma (RCC), sponsored by Fox Chase Cancer Center. Started Aug 2015; status: terminated.
02
Drugs
ixazomib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT02447887.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447887.